FR3110916A1 - PRODUITS & PROCEDES - Google Patents
PRODUITS & PROCEDES Download PDFInfo
- Publication number
- FR3110916A1 FR3110916A1 FR2105486A FR2105486A FR3110916A1 FR 3110916 A1 FR3110916 A1 FR 3110916A1 FR 2105486 A FR2105486 A FR 2105486A FR 2105486 A FR2105486 A FR 2105486A FR 3110916 A1 FR3110916 A1 FR 3110916A1
- Authority
- FR
- France
- Prior art keywords
- methods
- products
- relates
- cas
- crrnas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000010453 CRISPR/Cas method Methods 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
L'invention porte sur des procédés de modification de génomes cellulaires de manière synergique par utilisation de plusieurs systèmes CRISPR/Cas. L'invention porte également sur des compositions, des ARNcr, des Cas et des vecteurs pour mettre en œuvre de tels procédés. Fig. 2
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2007943.0 | 2020-05-27 | ||
GBGB2007943.0A GB202007943D0 (en) | 2020-05-27 | 2020-05-27 | Products & methods |
Publications (1)
Publication Number | Publication Date |
---|---|
FR3110916A1 true FR3110916A1 (fr) | 2021-12-03 |
Family
ID=71406263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR2105486A Pending FR3110916A1 (fr) | 2020-05-27 | 2021-05-27 | PRODUITS & PROCEDES |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP4158021A1 (fr) |
JP (1) | JP2023527819A (fr) |
CN (1) | CN115552007A (fr) |
CA (1) | CA3171200A1 (fr) |
FR (1) | FR3110916A1 (fr) |
GB (1) | GB202007943D0 (fr) |
WO (1) | WO2021239758A1 (fr) |
Citations (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014191518A1 (fr) * | 2013-05-29 | 2014-12-04 | Cellectis | Procédé visant à produire un clivage d'adn précis par l'activité de cas9 nickase |
WO2015006294A2 (fr) * | 2013-07-10 | 2015-01-15 | President And Fellows Of Harvard College | Protéines cas9 orthogonales pour la régulation et l'édition de gènes avec arn guide |
US20150064138A1 (en) | 2013-09-05 | 2015-03-05 | Massachusetts Institute Of Technology | Tuning microbial populations with programmable nucleases |
WO2015066119A1 (fr) | 2013-10-30 | 2015-05-07 | North Carolina State University | Compositions et méthodes liées à un système crispr-cas de type ii chez lactobacillus buchneri |
WO2015136541A2 (fr) | 2014-03-12 | 2015-09-17 | Yeda Research And Development Co. Ltd | Réduction des niveaux ou de l'activité systémiques des lymphocytes t régulateurs en vue du traitement de maladies et de lésions touchant le snc |
US20160024510A1 (en) | 2013-02-07 | 2016-01-28 | The Rockefeller University | Sequence specific antimicrobials |
WO2016033246A1 (fr) * | 2014-08-27 | 2016-03-03 | Caribou Biosciences, Inc. | Procédés pour augmenter l'efficacité de l'ingénierie médiée par cas9 |
US20160115488A1 (en) | 2012-12-12 | 2016-04-28 | The Broad Institute Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
WO2016177682A1 (fr) | 2015-05-06 | 2016-11-10 | Snipr Technologies Limited | Altération de populations microbiennes et modification de microbiote |
US20160345578A1 (en) | 2015-05-29 | 2016-12-01 | North Carolina State University | Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids |
WO2016205623A1 (fr) | 2015-06-17 | 2016-12-22 | North Carolina State University | Méthodes et compositions pour l'édition de génome dans des bactéries à l'aide de systèmes cas9-crispr |
WO2016205276A1 (fr) * | 2015-06-15 | 2016-12-22 | North Carolina State University | Procédés et compositions permettant une délivrance efficace d'acides nucléiques et d'antimicrobiens à base d'arn |
US20170022499A1 (en) | 2014-04-03 | 2017-01-26 | Massachusetts Institute Of Techology | Methods and compositions for the production of guide rna |
US20170175142A1 (en) | 2012-12-12 | 2017-06-22 | The Broad Institute Inc. | Crispr-cas systems and methods for altering expression of gene products |
WO2017112620A1 (fr) | 2015-12-22 | 2017-06-29 | North Carolina State University | Méthodes et compositions pour l'administration d'agents antimicrobiens à base de crispr |
WO2017118598A1 (fr) | 2016-01-10 | 2017-07-13 | Snipr Technologies Limited | Brins d'acides nucléiques recombinogéniques in situ |
WO2017219033A1 (fr) * | 2016-06-17 | 2017-12-21 | Montana State University | Ciblage bidirectionnel permettant l'édition de génome |
WO2018081502A1 (fr) | 2016-10-28 | 2018-05-03 | Massachusetts Intitute Of Technology | Bactériophages synthétiques et compositions bactériophages |
US20180140698A1 (en) | 2016-06-05 | 2018-05-24 | Snipr Technologies Limited | Selectively altering microbiota for immune modulation |
US20180200342A1 (en) | 2015-07-13 | 2018-07-19 | Institut Pasteur | Improving sequence-specific antimicrobials by blocking dna repair |
EP3356533A1 (fr) | 2015-09-28 | 2018-08-08 | North Carolina State University | Méthodes et compositions pour agents antimicrobiens spécifiques d'une séquence |
EP3362571A2 (fr) | 2015-10-13 | 2018-08-22 | Duke University | Ingénierie génomique avec systèmes crispr de type i dans des cellules eucaryotes |
US20180273940A1 (en) | 2018-04-30 | 2018-09-27 | Snipr Biome Aps | Treating and preventing microbial infections |
WO2019002207A1 (fr) * | 2017-06-25 | 2019-01-03 | Snipr Technologies Limited | Vecteurs & méthodes |
WO2019002218A2 (fr) | 2017-06-25 | 2019-01-03 | Snipr Technologies Limited | Modification de populations microbiennes et modification de microbiote |
US20190160120A1 (en) | 2017-11-29 | 2019-05-30 | Snipr Biome Aps | Dna, methods etc |
WO2019144061A1 (fr) | 2018-01-19 | 2019-07-25 | Duke University | Ingénierie génomique avec des systèmes crispr-cas dans des eucaryotes |
WO2019152519A1 (fr) * | 2018-01-30 | 2019-08-08 | Editas Medicine, Inc. | Systèmes et procédés de modulation de réarrangements chromosomiques |
WO2019185551A1 (fr) | 2018-03-25 | 2019-10-03 | Snipr Biome Aps. | Traitement et prévention des infections microbiennes |
WO2019213592A1 (fr) * | 2018-05-04 | 2019-11-07 | Locus Biosciences, Inc. | Procédés et compositions pour détruire une bactérie cible |
WO2019227080A1 (fr) | 2018-05-25 | 2019-11-28 | Locus Biosciences, Inc. | Procédés et compositions pour détruire une bactérie cible |
WO2019236566A1 (fr) | 2018-06-05 | 2019-12-12 | Lifeedit, Inc. | Nucléases guidées par arn et fragments actifs et variants associés et méthodes d'utilisation |
WO2020072254A1 (fr) | 2018-10-01 | 2020-04-09 | North Carolina State University | Système crispr-cas de type i recombinant et ses utilisations pour tuer des cellules cibles |
WO2020072248A1 (fr) | 2018-10-01 | 2020-04-09 | North Carolina State University | Système crispr-cas de type i recombinant |
WO2020072253A1 (fr) | 2018-10-01 | 2020-04-09 | North Carolina State University | Système crispr-cas de type i recombinant et ses utilisations pour le criblage de cellules variantes |
WO2020072250A1 (fr) | 2018-10-01 | 2020-04-09 | North Carolina State University | Système crispr-cas de type i recombinant et utilisations de ce dernbier pour la modification du génome et la modification de l'expression |
US20200115716A1 (en) | 2018-10-14 | 2020-04-16 | Snipr Biome Aps | Single-vector type i vectors |
WO2020240523A1 (fr) * | 2019-05-31 | 2020-12-03 | The Governing Council Of The University Of Toronto | Procédés et compositions pour l'édition de gènes multiplex |
WO2021092254A1 (fr) * | 2019-11-06 | 2021-05-14 | Locus Biosciences, Inc. | Compositions de phage comprenant les systèmes crispr-cas et leurs procédés d'utilisation |
-
2020
- 2020-05-27 GB GBGB2007943.0A patent/GB202007943D0/en not_active Ceased
-
2021
- 2021-05-26 EP EP21728227.6A patent/EP4158021A1/fr not_active Withdrawn
- 2021-05-26 CN CN202180038118.1A patent/CN115552007A/zh active Pending
- 2021-05-26 JP JP2022572491A patent/JP2023527819A/ja active Pending
- 2021-05-26 WO PCT/EP2021/063954 patent/WO2021239758A1/fr unknown
- 2021-05-26 CA CA3171200A patent/CA3171200A1/fr active Pending
- 2021-05-27 FR FR2105486A patent/FR3110916A1/fr active Pending
Patent Citations (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160115488A1 (en) | 2012-12-12 | 2016-04-28 | The Broad Institute Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
US20180179547A1 (en) | 2012-12-12 | 2018-06-28 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
US20170175142A1 (en) | 2012-12-12 | 2017-06-22 | The Broad Institute Inc. | Crispr-cas systems and methods for altering expression of gene products |
US20160024510A1 (en) | 2013-02-07 | 2016-01-28 | The Rockefeller University | Sequence specific antimicrobials |
US20160324938A1 (en) | 2013-02-07 | 2016-11-10 | The Rockefeller University | Sequence specific antimicrobials |
WO2014191518A1 (fr) * | 2013-05-29 | 2014-12-04 | Cellectis | Procédé visant à produire un clivage d'adn précis par l'activité de cas9 nickase |
WO2015006294A2 (fr) * | 2013-07-10 | 2015-01-15 | President And Fellows Of Harvard College | Protéines cas9 orthogonales pour la régulation et l'édition de gènes avec arn guide |
US20150064138A1 (en) | 2013-09-05 | 2015-03-05 | Massachusetts Institute Of Technology | Tuning microbial populations with programmable nucleases |
WO2015066119A1 (fr) | 2013-10-30 | 2015-05-07 | North Carolina State University | Compositions et méthodes liées à un système crispr-cas de type ii chez lactobacillus buchneri |
WO2015136541A2 (fr) | 2014-03-12 | 2015-09-17 | Yeda Research And Development Co. Ltd | Réduction des niveaux ou de l'activité systémiques des lymphocytes t régulateurs en vue du traitement de maladies et de lésions touchant le snc |
US20170022499A1 (en) | 2014-04-03 | 2017-01-26 | Massachusetts Institute Of Techology | Methods and compositions for the production of guide rna |
WO2016033246A1 (fr) * | 2014-08-27 | 2016-03-03 | Caribou Biosciences, Inc. | Procédés pour augmenter l'efficacité de l'ingénierie médiée par cas9 |
WO2016177682A1 (fr) | 2015-05-06 | 2016-11-10 | Snipr Technologies Limited | Altération de populations microbiennes et modification de microbiote |
US20170246221A1 (en) | 2015-05-06 | 2017-08-31 | Snipr Technologies Limited | Altering microbial populations & modifying microbiota |
US20160345578A1 (en) | 2015-05-29 | 2016-12-01 | North Carolina State University | Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids |
WO2016205276A1 (fr) * | 2015-06-15 | 2016-12-22 | North Carolina State University | Procédés et compositions permettant une délivrance efficace d'acides nucléiques et d'antimicrobiens à base d'arn |
EP3307872A1 (fr) | 2015-06-15 | 2018-04-18 | North Carolina State University | Procédés et compositions permettant une délivrance efficace d'acides nucléiques et d'antimicrobiens à base d'arn |
US20180155729A1 (en) | 2015-06-15 | 2018-06-07 | North Carolina State University | Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials |
WO2016205623A1 (fr) | 2015-06-17 | 2016-12-22 | North Carolina State University | Méthodes et compositions pour l'édition de génome dans des bactéries à l'aide de systèmes cas9-crispr |
US20180200342A1 (en) | 2015-07-13 | 2018-07-19 | Institut Pasteur | Improving sequence-specific antimicrobials by blocking dna repair |
EP3356533A1 (fr) | 2015-09-28 | 2018-08-08 | North Carolina State University | Méthodes et compositions pour agents antimicrobiens spécifiques d'une séquence |
EP3362571A2 (fr) | 2015-10-13 | 2018-08-22 | Duke University | Ingénierie génomique avec systèmes crispr de type i dans des cellules eucaryotes |
WO2017112620A1 (fr) | 2015-12-22 | 2017-06-29 | North Carolina State University | Méthodes et compositions pour l'administration d'agents antimicrobiens à base de crispr |
WO2017118598A1 (fr) | 2016-01-10 | 2017-07-13 | Snipr Technologies Limited | Brins d'acides nucléiques recombinogéniques in situ |
US20180140698A1 (en) | 2016-06-05 | 2018-05-24 | Snipr Technologies Limited | Selectively altering microbiota for immune modulation |
WO2017219033A1 (fr) * | 2016-06-17 | 2017-12-21 | Montana State University | Ciblage bidirectionnel permettant l'édition de génome |
WO2018081502A1 (fr) | 2016-10-28 | 2018-05-03 | Massachusetts Intitute Of Technology | Bactériophages synthétiques et compositions bactériophages |
WO2019002218A2 (fr) | 2017-06-25 | 2019-01-03 | Snipr Technologies Limited | Modification de populations microbiennes et modification de microbiote |
WO2019002207A1 (fr) * | 2017-06-25 | 2019-01-03 | Snipr Technologies Limited | Vecteurs & méthodes |
WO2019105821A1 (fr) | 2017-11-29 | 2019-06-06 | Snipr Biome Aps. | Phage et particules de transduction |
US20190160120A1 (en) | 2017-11-29 | 2019-05-30 | Snipr Biome Aps | Dna, methods etc |
WO2019144061A1 (fr) | 2018-01-19 | 2019-07-25 | Duke University | Ingénierie génomique avec des systèmes crispr-cas dans des eucaryotes |
WO2019152519A1 (fr) * | 2018-01-30 | 2019-08-08 | Editas Medicine, Inc. | Systèmes et procédés de modulation de réarrangements chromosomiques |
WO2019185551A1 (fr) | 2018-03-25 | 2019-10-03 | Snipr Biome Aps. | Traitement et prévention des infections microbiennes |
US20180273940A1 (en) | 2018-04-30 | 2018-09-27 | Snipr Biome Aps | Treating and preventing microbial infections |
WO2019213592A1 (fr) * | 2018-05-04 | 2019-11-07 | Locus Biosciences, Inc. | Procédés et compositions pour détruire une bactérie cible |
WO2019227080A1 (fr) | 2018-05-25 | 2019-11-28 | Locus Biosciences, Inc. | Procédés et compositions pour détruire une bactérie cible |
WO2019236566A1 (fr) | 2018-06-05 | 2019-12-12 | Lifeedit, Inc. | Nucléases guidées par arn et fragments actifs et variants associés et méthodes d'utilisation |
WO2020072254A1 (fr) | 2018-10-01 | 2020-04-09 | North Carolina State University | Système crispr-cas de type i recombinant et ses utilisations pour tuer des cellules cibles |
WO2020072248A1 (fr) | 2018-10-01 | 2020-04-09 | North Carolina State University | Système crispr-cas de type i recombinant |
WO2020072253A1 (fr) | 2018-10-01 | 2020-04-09 | North Carolina State University | Système crispr-cas de type i recombinant et ses utilisations pour le criblage de cellules variantes |
WO2020072250A1 (fr) | 2018-10-01 | 2020-04-09 | North Carolina State University | Système crispr-cas de type i recombinant et utilisations de ce dernbier pour la modification du génome et la modification de l'expression |
US20200115716A1 (en) | 2018-10-14 | 2020-04-16 | Snipr Biome Aps | Single-vector type i vectors |
WO2020078893A1 (fr) | 2018-10-14 | 2020-04-23 | Snipr Biome Aps. | Produits, utilisations et méthodes |
WO2020240523A1 (fr) * | 2019-05-31 | 2020-12-03 | The Governing Council Of The University Of Toronto | Procédés et compositions pour l'édition de gènes multiplex |
WO2021092254A1 (fr) * | 2019-11-06 | 2021-05-14 | Locus Biosciences, Inc. | Compositions de phage comprenant les systèmes crispr-cas et leurs procédés d'utilisation |
Non-Patent Citations (2)
Title |
---|
LIAN JIAZHANG ET AL: "Combinatorial metabolic engineering using an orthogonal tri-functional CRISPR system", NATURE COMMUNICATIONS, vol. 8, no. 1, 22 November 2017 (2017-11-22), UK, pages 1688, XP055835836, ISSN: 2041-1723, Retrieved from the Internet <URL:https://www.nature.com/articles/s41467-017-01695-x.pdf> DOI: 10.1038/s41467-017-01695-x * |
LUTZBUJARD, NUCLEIC ACIDS RESEARCH, vol. 25, 1997, pages 1203 - 1210 |
Also Published As
Publication number | Publication date |
---|---|
JP2023527819A (ja) | 2023-06-30 |
GB202007943D0 (en) | 2020-07-08 |
CA3171200A1 (fr) | 2021-12-02 |
EP4158021A1 (fr) | 2023-04-05 |
WO2021239758A1 (fr) | 2021-12-02 |
CN115552007A (zh) | 2022-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
WO2020243415A3 (fr) | Inhibiteurs de tead et leurs utilisations | |
MX2022007527A (es) | Inhibidores de proteinas kras mutantes. | |
MX2019012431A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. | |
MX2022015272A (es) | Inhibidores de la proteina kras g12c y usos de estos. | |
WO2020039321A3 (fr) | Anticorps anti-gdf15, compositions et procédés d'utilisation | |
MX2023008031A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
MX2021012216A (es) | Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos. | |
MD3442972T2 (ro) | Inhibitori ai bromodomeniului | |
PH12020551352A1 (en) | Arginase inhibitors | |
PH12021500008A1 (en) | Transglutaminase 2 (tg2) inhibitors | |
MX2022006206A (es) | Compuestos macrociclicos sustituidos y metodos de tratamiento relacionados. | |
MX2022003166A (es) | Moduladores de il-17a y usos de los mismos. | |
EA202192146A1 (ru) | Антитела к клаудину 6 и их применение | |
MX2021015156A (es) | Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos. | |
MX2017015923A (es) | Inhibidores de indolamina-2,3-dioxigenasa (ido). | |
MX2022007841A (es) | Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos. | |
MX2021006674A (es) | Composiciones para estabilizar bacterias y usos de las mismas. | |
MX2020007562A (es) | Nuevas antranilamidas, su uso como insecticida y procesos para su preparacion. | |
FR3110916A1 (fr) | PRODUITS &amp; PROCEDES | |
MX2023003973A (es) | Degradadores de transductores de señales y activadores de la transcripción (stat) y usos de los mismos. | |
MX2023006719A (es) | Degradadores de cinasas asociadas con el receptor de interleucina 1 (irak) y sus usos. | |
MX2022011437A (es) | Degradadores de transductores de se?al y activadores de la transcripcion (stat) y usos de los mismos. | |
MX2022015299A (es) | Metodos para integracion genomica estable en microorganismos recombinantes. | |
AU2020378127A8 (en) | Compounds as CD73 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 2 |
|
PLSC | Publication of the preliminary search report |
Effective date: 20230120 |
|
PLFP | Fee payment |
Year of fee payment: 3 |
|
RX | Complete rejection |
Effective date: 20240208 |